Pfizer recognizes the public concern in relation to the COVID-19 pandemic, which continues to evolve. We are actively monitoring the situation across the globe, assessing the implications to our patients, colleagues and company, and taking actions to support continued health and safety. This involves an unprecedented call for cross-industry collaboration as addressed in our Five-Point plan issued on Friday, March 13.

Pfizer operates one of the most sophisticated supply chain systems in the industry with over 40 Pfizer-owned sites and over 200 suppliers globally, which provides capacity and redundancy as needed. We consistently and diligently monitor the supply of our medicines. As of now, we have not seen any disruption in our hemophilia product supply chain or impact to our business. Our plants are currently running in compliance with government regulations and supported by colleagues whose physical presence is required to manufacture and supply products.

As the COVID-19 pandemic is an evolving situation, we will continue to support our customers and patients to ensure that patients receive the medicines they need, while following local government guidance to ensure the health and safety of our colleagues, customers and the community.

For additional information and resources from Pfizer related to the novel coronavirus outbreak, please refer to https://www.pfizer.com/health/coronavirus or for any questions about Pfizer’s products, please contact Pfizer Medical Information at 1-800-438-1985.

Sincerely,

David Kuperstein
Senior Director, Rare Hemophilia, Endocrine and Metabolic US Marketing Lead, Rare Disease North America